A novel orthotopic implantation model of human esophageal carcinoma in nude rats: CD44H mediates cancer cell invasion in vitro and in vivo.
A new orthotopic esophageal cancer model was developed by implanting fragments of xenografts of T.T human esophageal squamous carcinoma cells into the cervical esophagus of athymic rats. The rats had symptoms analogous to the human clinical course such as respiratory distress, dysphagia, vomiting of blood, or Horner syndrome, followed by death resulting from suffocation. Microscopic metastases of lymph node were observed around the tumor in 3 of 18 rats. A new cell line (T.T-1) was established from these metastases. Flow cytometry showed that T.T-1 and T.T parental cells had nearly the same surface levels of beta1-integrin, alpha2-integrin, alpha3-integrin and E-cadherin, and no expression of CD44v3, CD44v6 and alpha5-integrin. T.T-1 cells had a higher level of CD44H, however, and a greater binding efficiency to the extracellular matrix components; laminin, type IV collagen, hyaluronic acid, and fibronectin than T.T cells. Anti-CD44H antibody significantly decreased the binding efficiency of T.T-1 cells. T.T-1 cells were also significantly more invasive than T.T cells through all the extracellular matrix components except hyaluronic acid. After orthotopic implantation histological examination showed that T.T-1 tumors invaded beyond the esophageal mucosa and tracheal muscle layer and obstructed the esophagus and trachea. No invasion was observed with T.T tumors. Rats with T.T-1 or T.T tumors survived an average of 32.0 and 50.7 days, respectively (p < 0.01). In addition T.T-1 tumors expressed higher levels of CD44H mRNA than T.T tumors. In summary, our newly developed orthotopic implantation model is a valid model of esophageal cancer because it followed the same clinical course experienced by humans. Moreover, using cells derived from this model, we were able to demonstrate that CD44H is involved in esophageal cancer cell invasion.
Hori
T
T
First Department of Surgery, Osaka City University Medical School, Osaka, Japan. helji@med.osaka-cu.ac.jp
Yamashita
Y
Y
Ohira
M
M
Matsumura
Y
Y
Muguruma
K
K
Hirakawa
K
K
D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D015820:Cadherins / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology; D002448:Cell Adhesion; D003094:Collagen / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D004938:Esophageal Neoplasms / Q000473:pathology*; D004947:Esophagus / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D005353:Fibronectins / Q000378:metabolism; D005434:Flow Cytometry; D006023:Glycoproteins / Q000096:biosynthesis; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis / Q000378:metabolism*; D006820:Hyaluronic Acid / Q000378:metabolism; D039421:Integrin alpha2; D039422:Integrin alpha3; D019012:Integrin beta1 / Q000096:biosynthesis; D016023:Integrins / Q000096:biosynthesis; D007797:Laminin / Q000378:metabolism; D008198:Lymph Nodes / Q000473:pathology; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation / Q000379:methods*; D011485:Protein Binding; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011923:Rats, Nude; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014132:Trachea / Q000378:metabolism; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; C121450:CD44V3,8-10; C112697:CD44v6 antigen; D015820:Cadherins; D005353:Fibronectins; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D039421:Integrin alpha2; D039422:Integrin alpha3; D019012:Integrin beta1; D016023:Integrins; D007797:Laminin; D012333:RNA, Messenger; D006820:Hyaluronic Acid; D003094:Collagen